Patents by Inventor Jean-Pierre Hardelin

Jean-Pierre Hardelin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic composition comprising the KAL protein and use of the KAL protein for the treatment of retinal, renal, neuronal and neural injury
    Publication number: 20070037736
    Abstract: KAL protein is identified the active agent in a therapeutic composition for treatment of injury to nerve tissue, including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein. The therapeutic agent may be administered locally, or intravenously. Retinal disorders may be similarly treated.
    Type: Application
    Filed: June 29, 2006
    Publication date: February 15, 2007
    Applicants: INSTITUT PASTEUR, Centre National De La Recherche Scient.
    Inventors: Christine Petit, Nadia Soussi-Yanicostas, Jean-Pierre Hardelin, Catherine Sarailh, Genevieve Rougon, Renaud Legouis, Olivier Ardouin, Jean-Claude Mazie
  • Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuronal and neural injury
    Patent number: 6770743
    Abstract: KAL protein is identified the active agent in a therapeutic composition for treatment of injury to nerve tissue, including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein. The therapeutic agent may be administered locally, or intravenously. Retinal disorders may be similarly treated.
    Type: Grant
    Filed: August 16, 2002
    Date of Patent: August 3, 2004
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Christine Petit, Nadia Soussi-Yanticostas, Jean-Pierre Hardelin, Catherine Sarailh, Genevieve Rougon, Renaud Legouis, Olivier Ardouin, Jean-Claude Mazie
  • Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuronal and neural injury
    Patent number: 6548475
    Abstract: KAL protein is identified as the active agent in a therapeutic composition for treatment of injury to nerve tissue, including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein. The therapeutic agent may be administered locally, or intravenously. Retinal disorders may be similarly treated.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: April 15, 2003
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Christine Petit, Nadia Soussi-Yanticostas, Jean-Pierre Hardelin, Catherine Sarailh, Genevieve Rougon, Renaud Legouis, Olivier Ardouin, Jean-Claude Mazie
  • Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuronal and neural injury
    Publication number: 20030060401
    Abstract: KAL protein is identified the active agent in a therapeutic composition for treatment of injury to nerve tissue, including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein. The therapeutic agent may be administered locally, or intravenously. Retinal disorders may be similarly treated.
    Type: Application
    Filed: August 16, 2002
    Publication date: March 27, 2003
    Applicant: INSTITUT PASTEUR
    Inventors: Christine Petit, Nadia Soussi-Yanticostas, Jean-Pierre Hardelin, Catherine Sarailh, Genevieve Rougon, Renaud Legouis, Olivier Ardouin, Jean-Claude Mazie
  • Therapeutic composition comprising the KAL protein and use of the KAL protein for the treatment of retinal, renal, neuronal and neural injury
    Publication number: 20020123467
    Abstract: KAL protein is identified the active agent in a therapeutic composition for treatment of injury to nerve tissue including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein. The therapeutic agent may be administered locally, or intravenously. Retinal disorders may be similarly treated.
    Type: Application
    Filed: April 11, 2002
    Publication date: September 5, 2002
    Applicant: INSTITUT PASTEUR
    Inventors: Christine Petit, Nadia Soussi-Yanicostas, Jean-Pierre Hardelin, Catherine Sarailh, Genevieve Rougon, Renaud Legouis, Olivier Ardouin, Jean-Claude Mazie
  • Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuromal and neural injury
    Patent number: 6121231
    Abstract: KAL protein is identified the active agent in a therapeutic composition for treatment of injury to nerve tissue, including spinal cord tissue, as well as support of treatment for renal grafts. Additionally, therapeutic treatment of renal injury, and kidney transplantation and renal surgery, is effected by administration of KAL protein. The therapeutic agent may be administered locally, or intravenously. Retinal disorders may be similarly treated.
    Type: Grant
    Filed: December 6, 1996
    Date of Patent: September 19, 2000
    Assignees: Institut Pasteur, Centre Nationale de la Recherche Scientifique
    Inventors: Christine Petit, Nadia Soussi-Yanticostas, Jean-Pierre Hardelin, Catherine Sarailh, Genevieve Rougon, Renaud Legouis, Olivier Ardouin, Jean-Claude Mazie
  • Gene associated with X linked Kallmann syndrome and diagnostic applications therefrom
    Patent number: 5763166
    Abstract: The invention relates to a fragment of nucleic acid characterized in that it comprises a nucleotide sequence selected from: (A) the sequence SEQ ID No. 1; (B) the sequences of one or more bases; (C) fragments of the said sequences (A) and (B); (D) sequences complementary to the said sequences (A), (B), and (C); and (E) the sequences which hybridize with the sequences (A),(B), and (C). The corresponding peptide sequences are also disclosed. A nucleic acid fragment of the invention may be used as a primer or probe, particularly in a method for diagnosing a genetic anomaly linked to the Kallmann syndrome.
    Type: Grant
    Filed: June 30, 1994
    Date of Patent: June 9, 1998
    Assignees: Institut Pasteur, The United States of America as represented by the Department of Health and Human Services
    Inventors: Christine Petit, Jean-Michel Claverie, Jacuqeline Levilliers, Renaud Legouis, Jean-Pierre Hardelin, Georges Lutfalla